{"slug":"ss-31-glp-1","verification":{"valid":true,"entries":2,"head":"5339d8ba65011c316cae670bddc828ac77b16f9fca27114280405e7523ee1738"},"energy":{"passes":2,"tokens_in":16822,"tokens_out":3169,"tokens_total":19991,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"5339d8ba65011c316cae670bddc828ac77b16f9fca27114280405e7523ee1738"},"provenance":[{"ts":"2026-06-29T23:55:00.909Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Ss 31 for Glp 1\nSlug: ss-31-glp-1\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\"}],\"drugs_in_scope\":[\"glp1-agonists\"],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\",\"section_title\":\"Why SS-31 (Elamipretide) might help you\",\"layer\":\"mitochondrial\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[{\"drug\":\"glp1-agonists\",\"name\":\"GLP-1 agonists (class)\",\"section_title\":\"Why GLP-1 agonists (class) matters for you\",\"steps\":[\"**Drug:** GLP-1 agonists (class)\",\"**What it does:** Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss.\",\"**Therefore for you:** state whether this drug **reduces load**, **suppresses a signal**, or **supports metabolism** — and whether that helps or trades off repair for your condition.\"],\"prose\":\"1. **Drug:** GLP-1 agonists (class)\\n2. **What it does:** Metabolic benefit vs gut slowing / muscle loss","response":"{\n  \"slug\": \"ss-31-glp-1\",\n  \"title\": \"SS-31 (Elamipretide) Mitochondrial Targeting with GLP-1 Agonists: Evidence Layers\",\n  \"body\": \"## What's breaking down\\n\\nMitochondrial energy production can decline with age, metabolic stress, or rapid body composition changes. GLP-1 agonists drive weight loss through appetite reduction and slower gastric emptying. This often produces 1–2+ lb weekly loss, which can include lean mass if protein intake and resistance training lag. Each pound of body weight lost removes roughly 4 lb of compressive force from the spine and joints during daily movement, but the metabolic shift may also increase cellular stress on mitochondria in muscle and other tissues.\\n\\nSS-31 (elamipretide) is studied for its ability to bind cardiolipin in the inner mitochondrial membrane. This interaction is discussed in preclinical work as supporting electron transport chain efficiency and lowering reactive oxygen species. The article focuses on whether this mitochondrial layer interacts with the metabolic changes seen during GLP-1 use.\\n\\n## Why SS-31 (Elamipretide) might help you\\n\\nIf mitochondrial bioenergetics form part of your situation while using GLP-1 agonists, SS-31 is examined because it targets repair at the mitochondrial membrane rather than symptom masking.\\n\\n1. GLP-1 driven weight loss alters energy demand and substrate use.\\n2. Mitochondria in muscle and other tissues may experience increased oxidative load during this transition.\\n3. SS-31 concentrates in the inner mitochondrial membrane and associates with cardiolipin.\\n4. Preclinical models show this association correlates with improved ATP production and reduced electron leak.\\n5. Therefore, if mitochondrial efficiency is a limiting factor for you during GLP-1 therapy, the peptide is studied for direct membrane stabilization rather than downstream metabolic signaling.\\n\\n## Why GLP-1 agonists (class) matters for you\\n\\nGLP-1 agonists primarily support metabolism by enhancing insulin secre","tokens_in":16822,"tokens_out":3169,"cost":0,"prev":"genesis","hash":"b87817cb8e5059cccfd97de54c43ac8e324a2d6052fe5c7a99d78446c55fb156"},{"ts":"2026-07-17T02:42:03.325Z","model":"owner","action":"voxel_divide","prompt":"","input":"ss-31-glp-1","response":"23 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"b87817cb8e5059cccfd97de54c43ac8e324a2d6052fe5c7a99d78446c55fb156","hash":"5339d8ba65011c316cae670bddc828ac77b16f9fca27114280405e7523ee1738"}]}